Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Phase III, randomized, open-label, multicentre, active-controlled, non-inferiority study
evaluating the efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) in
single-pill, in HIV-1 infected individuals currently taking an INSTI-based three-drug
first-line regimen for less than 18 months and who have been virologically suppressed with
HIV-1 RNA <50 copies/mL
Phase:
Phase 3
Details
Lead Sponsor:
Societa' Italiana Di Malattie Infettive E Tropicali